Premium
Targeting glioblastoma stem cells ( GSC s) with peroxisome proliferator‐activated receptor gamma ( PPAR γ) ligands
Author(s) -
Im ChangNim
Publication year - 2016
Publication title -
iubmb life
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 113
eISSN - 1521-6551
pISSN - 1521-6543
DOI - 10.1002/iub.1475
Subject(s) - peroxisome proliferator activated receptor , cancer stem cell , cancer research , stem cell , receptor , metastasis , nuclear receptor , biology , chemistry , microbiology and biotechnology , cancer , transcription factor , biochemistry , gene , genetics
Glioblastoma multiforme (GBM), also known as glioblastoma, is the most common and aggressive brain tumor. GBM has a poor survival rate and high resistance to standard therapy, leading to recurrence and metastasis to adjacent normal regions. Glioblastoma stem cells (GSCs) are regarded as an emerging target for therapy of GBM. Peroxisome proliferator‐activated receptor gamma (PPARγ) is a nuclear receptor that functions in a variety of cancers and in normal adipocyte differentiation. The newly discovered connection between PPARγ ligands and cancer stem cells (CSCs) raises important implications for the potential therapeutic use of synthetic PPARγ ligands, such as thiazolidinediones (TZDs), in glioblastoma. Here, I hypothesize that synthetic PPARγ ligands serve to modulate stemness‐related molecules and several signaling pathway in GSCs and I propose potential experimental approaches to investigate the effects of these ligands on GSCs in vitro and in vivo . © 2016 IUBMB Life, 68(3):173–177, 2016